MiNK Therapeutics (INKT) Earnings Date & Reports

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

INKT is expected to report earnings to rise 1.61% to -62 cents per share on November 13

MiNK Therapeutics INKT Stock Earnings Reports

Q3'26

Est.

$-0.63

Q2'26

Beat

by $0.25

Q1'26

Missed

by $0.39

Q4'25

Missed

by $0.44

Q3'25

Missed

by $0.58

The last earnings report on August 13 showed earnings per share of -62 cents, beating the estimate of -87 cents. With 5.67K shares outstanding, the current market capitalization sits at 62.26M.

View a ticker or compare two or three

INKT

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days